| Project/Area Number |
23659527
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Meiji Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | GM2ガングリオシドーシス / テイ-サックス病 / ザンドホッフ病 / GM2ガングリオシド / リゾ-GM2ガングリオシド / バイオマーカー / 1. GM2ガングリオシドーシス / 2. テイ-サックス病 / 3. ザンドホッフ病 / 4. GM2 ガングリオシド / 5. リゾGM2ガングリオシド / 6. バイオマーカー / テイ－サックス病 / リゾ－GM2ガングリオシド |
|---|
| Research Abstract |
To develop a new biomarker of GM2 gangliosidosis, we focused attention on lyso-GM2 ganglioside (lyso-GM2). We measured the lyso-GM2 levels in the brain and plasma of Sandhoff mice by means of high performance liquid chromatography, and examined the effects of a modified hexosaminidase B (HexB) exhibiting hexosaminidase A (HexA)-like activity. Then, the lyso-GM2 concentrations in plasma from patients with Tay-Sachs disease and Sandhoff disease were determined. The lyso-GM2 levels in the brain and plasma in Sandhoff mice were apparently increased compared with those in wild-type mice, and they decreased on intraventricular administration of the modified HexB. The plasma lyso-GM2 levels in the patients with Tay-Sachs disease and Sandhoff disease were increased, and their increase in lyso-GM2 was associated with a decrease in HexA activity. Considering the results, lyso-GM2 is thought to be a potential biomarker of GM2 gangliosidosis.
|
